LSTA Stock Analysis: Buy, Sell, or Hold?
LSTA - Lisata Therapeutics, Inc. Common Stock
$1.47
0.35 (31.25%)
â˛
5d:
+34.86%
30d:
-30.66%
90d:
-53.18%
WAIT
LOW Confidence
Analysis Updated: Aug 20, 2026 12:00 AM ET
Earnings: Aug 20, 2026
0d
Get Alerted When LSTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LSTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LSTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LSTA is currently trading at $1.47, which is considered fair relative to its 30-day fair value range of $0.76 to $2.75.
Technical Outlook: Technically, LSTA is in a strong downtrend. The price is approaching resistance at $1.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 31.2% recently.
Market Sentiment: LSTA scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+257.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LSTA is in a strong downtrend. The price is approaching resistance at $1.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 31.2% recently.
Market Sentiment: LSTA scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+257.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.76 -
$2.75
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (71/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+31.2%)
- BULLISH: Trading 257.1% below Wall St target ($4.00)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.76 -
$2.75
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.02
Resistance Level
$1.28
Current Trend
Strong Downtrend
Technical data as of
Aug 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.97
Wall Street Target
$4.00
(+257.1%)
Revenue Growth (YoY)
-90.0%
Share & Embed Analysis
Last updated: August 21, 2026 1:08 PM ET
Data refreshes hourly during market hours. Next update: 2:08 PM
Data refreshes hourly during market hours. Next update: 2:08 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LSTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 28 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
